Literature DB >> 31629631

Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor.

Yifeng Yang1, Yingxiu Li1, Yunlei Hou1, Mingze Qin1, Ping Gong1, Ju Liu2, Yanfang Zhao3.   

Abstract

A series of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydro-quinoxaline moiety were synthesized and evaluated for their antiproliferative activity against five human cancer cell lines (A549, H460, HT-29, MKN-45 and U87MG) in vitro. Most of the tested compounds exhibited more potent inhibitory activities than the positive control foretinib. Compound 1b, 1s and 1t were further examined for their inhibitory activity against c-Met kinase. The most promising compound 1s (with c-Met IC50 value of 1.42 nM) showed remarkable cytotoxicity against A549, H460, HT-29, MKN45 and U87MG cell lines with IC50 values of 0.39 μM, 0.18 μM, 0.38 μM, 0.81 μM, respectively. Their preliminary structure-activity relationships (SARs) study indicated that the replacement of the aromatic ring with the cyclohexane improved their antiproliferative activity.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Phenoxyquinoline derivatives; Antitumor activity; Synthesis; c-Met inhibitors

Year:  2019        PMID: 31629631     DOI: 10.1016/j.bmcl.2019.126666

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

Review 1.  Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present).

Authors:  Qian Zhang; Pengwu Zheng; Wufu Zhu
Journal:  Molecules       Date:  2020-06-08       Impact factor: 4.411

2.  microRNA-582 Potentiates Liver and Lung Metastasis of Gastric Carcinoma Cells Through the FOXO3-Mediated PI3K/Akt/Snail Pathway.

Authors:  Tianyu Xie; Di Wu; Shuo Li; Xiongguang Li; Lipeng Wang; Yixun Lu; Qiying Song; Xuehong Sun; Xinxin Wang
Journal:  Cancer Manag Res       Date:  2020-06-30       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.